MedTrace Logo

Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).

NCT04318405 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 327

Last updated 2023-07-19

No results posted yet for this study

Summary

Real-CHOICE - designed as a prospective, longitudinal, observational, non-interventional study - will investigate the attitude of patients and physicians towards IV (intravenous) iron therapy in general and IIM (iron isomaltoside 1000) treatment particularly before and after IIM treatment in iron deficient patients with or without anemia in the real-world clinical setting after commercial availability of this product in Switzerland.

Conditions

  • Iron-Deficiency Anemia
  • Iron-Deficiency

Interventions

DRUG

Iron isomaltoside 1000

Observation of real-life treatment with iron isomaltoside 1000 / Iron Derisomaltose 1000

Sponsors & Collaborators

  • Pierre Fabre Pharma AG

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-10
Primary Completion
2022-11-30
Completion
2022-11-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04318405 on ClinicalTrials.gov